Psoriatic Arthritis
News from the FDA/CDC
FDA approves Idacio as eighth adalimumab biosimilar in U.S.
Data for Idacio (adalimumab-aacf) showed safety, efficacy, and immunogenicity similar to Humira.
From the Journals
Ustekinumab matches TNF inhibitors for psoriatic arthritis in 3-year, real-world study
A real-world study comparing the interleukin-12/23 inhibitor ustekinumab with tumor necrosis factor inhibitors for psoriatic arthritis found...
From the Journals
Vaccination cuts long COVID risk for rheumatic disease patients
Although it’s possible the higher proportion of Omicron cases in vaccinated patients accounted for lower rates of long COVID, differences in...
From the Journals
Skinny-label biosimilars provide substantial savings to Medicare
The estimated savings to Medicare during 2015-2020 that resulted from competition with five of the first-to-market biosimilars with skinny labels...
Feature
Wide variance described in lab monitoring of conventional synthetic DMARDs
“The take-home message of this study is that everyone is doing something different, which means that the system likely has a lot of low-value...
Guidelines
New ACR vaccination guideline: Take your best shot
Vaccinate patients with rheumatic and musculoskeletal disease against flu and other vaccine-preventable disease whenever possible, experts say.
Conference Coverage
Retention rates high after biosimilar-to-biosimilar switch for inflammatory arthritis
Danish investigators studied how a government-mandated switch from one infliximab biosimilar to another affected patients with inflammatory...
From the Journals
Therapeutic drug monitoring pays off for arthritis patients
Patients who reduced their dosage of TNF-alpha inhibitor had less treatment failure and similar risk of adverse events, compared with standard...
From the Journals
Two biologics equally effective for extraintestinal manifestations of IBD
Ustekinumab and vedolizumab have similar effects on extraintestinal manifestations of inflammatory bowel disease, a real-world, retrospective...
News from the FDA/CDC
FDA approves upadacitinib (Rinvoq) for sixth indication
Upadacitinib’s approval for nonradiographic axial spondyloarthritis marks the sixth indication in the United States for the Janus kinase inhibitor...
From the Journals
Psoriatic arthritis has greater impact on women than men
Women with PsA were more likely to have worse disease burden, pain, fatigue, quality of life, and greater disability and work impairment compared...